145 related articles for article (PubMed ID: 23480248)
1. Suboxone misuse along the opiate maintenance treatment pathway.
Furst RT
J Addict Dis; 2013; 32(1):53-67. PubMed ID: 23480248
[TBL] [Abstract][Full Text] [Related]
2. Early experience with Suboxone maintenance therapy in Hungary.
Demetrovics Z; Farkas J; Csorba J; Németh A; Mervó B; Szemelyácz J; Fleischmann E; Kassai-Farkas A; Petke Z; Oroján T; Rózsa S; Rigó P; Funk S; Kapitány M; Kollár A; Rácz J
Neuropsychopharmacol Hung; 2009 Dec; 11(4):249-57. PubMed ID: 20150662
[TBL] [Abstract][Full Text] [Related]
3. Buprenorphine in the treatment of opiate dependence.
Wesson DR; Smith DE
J Psychoactive Drugs; 2010 Jun; 42(2):161-75. PubMed ID: 20648912
[TBL] [Abstract][Full Text] [Related]
4. A prospective, randomized, multicenter acceptability and safety study of direct buprenorphine/naloxone induction in heroin-dependent individuals.
Amass L; Pukeleviciene V; Subata E; Almeida AR; Pieri MC; D'Egidio P; Stankova Z; Costa A; Smyth BP; Sakoman S; Wei Y; Strang J
Addiction; 2012 Jan; 107(1):142-51. PubMed ID: 21749526
[TBL] [Abstract][Full Text] [Related]
5. The prevalence and correlates of buprenorphine inhalation amongst opioid substitution treatment (OST) clients in Australia.
Horyniak D; Dietze P; Larance B; Winstock A; Degenhardt L
Int J Drug Policy; 2011 Mar; 22(2):167-71. PubMed ID: 21112758
[TBL] [Abstract][Full Text] [Related]
6. Medically assisted recovery from opiate dependence within the context of the UK drug strategy: methadone and Suboxone (buprenorphine-naloxone) patients compared.
McKeganey N; Russell C; Cockayne L
J Subst Abuse Treat; 2013 Jan; 44(1):97-102. PubMed ID: 22703715
[TBL] [Abstract][Full Text] [Related]
7. Buprenorphine and naloxone interactions in methadone maintenance patients.
Mendelson J; Jones RT; Welm S; Brown J; Batki SL
Biol Psychiatry; 1997 Jun; 41(11):1095-101. PubMed ID: 9146820
[TBL] [Abstract][Full Text] [Related]
8. Opioid maintenance treatment as a harm reduction tool for opioid-dependent individuals in New York City: the need to expand access to buprenorphine/naloxone in marginalized populations.
Stancliff S; Joseph H; Fong C; Furst T; Comer SD; Roux P
J Addict Dis; 2012; 31(3):278-87. PubMed ID: 22873189
[TBL] [Abstract][Full Text] [Related]
9. Using buprenorphine to facilitate entry into residential therapeutic community rehabilitation.
Collins ED; Horton T; Reinke K; Amass L; Nunes EV
J Subst Abuse Treat; 2007 Mar; 32(2):167-75. PubMed ID: 17306725
[TBL] [Abstract][Full Text] [Related]
10. Can the chronic administration of the combination of buprenorphine and naloxone block dopaminergic activity causing anti-reward and relapse potential?
Blum K; Chen TJ; Bailey J; Bowirrat A; Femino J; Chen AL; Simpatico T; Morse S; Giordano J; Damle U; Kerner M; Braverman ER; Fornari F; Downs BW; Rector C; Barh D; Oscar-Berman M
Mol Neurobiol; 2011 Dec; 44(3):250-68. PubMed ID: 21948099
[TBL] [Abstract][Full Text] [Related]
11. Use and misuse of opioid replacement therapies: a Queensland study.
Smirnov A; Kemp R
Subst Use Misuse; 2012 Jan; 47(1):78-85. PubMed ID: 22216993
[TBL] [Abstract][Full Text] [Related]
12. Less pain, more gain: buprenorphine-naloxone and patient retention in treatment.
Renzelli CM; Capretto NA
J Addict Dis; 2006; 25(3):97-104. PubMed ID: 16956874
[TBL] [Abstract][Full Text] [Related]
13. The clinical efficacy and abuse potential of combination buprenorphine-naloxone in the treatment of opioid dependence.
Mammen K; Bell J
Expert Opin Pharmacother; 2009 Oct; 10(15):2537-44. PubMed ID: 19708849
[TBL] [Abstract][Full Text] [Related]
14. Abuse liability of intravenous buprenorphine/naloxone and buprenorphine alone in buprenorphine-maintained intravenous heroin abusers.
Comer SD; Sullivan MA; Vosburg SK; Manubay J; Amass L; Cooper ZD; Saccone P; Kleber HD
Addiction; 2010 Apr; 105(4):709-18. PubMed ID: 20403021
[TBL] [Abstract][Full Text] [Related]
15. Preference for buprenorphine/naloxone and buprenorphine among patients receiving buprenorphine maintenance therapy in France: a prospective, multicenter study.
Daulouède JP; Caer Y; Galland P; Villeger P; Brunelle E; Bachellier J; Piquet JM; Harbonnier J; Leglise Y; Courty P
J Subst Abuse Treat; 2010 Jan; 38(1):83-9. PubMed ID: 19800758
[TBL] [Abstract][Full Text] [Related]
16. [Changes in psychosocial symptoms of opiate users over six months with buprenorphine/naloxone substitution therapy].
Petke Z; Csorba J; Meszaros J; Vingender I; Farkas J; Demetrovics Z; Kovacs Z; Menczel Z; Pataki Z; Simor P; Havasi A; Melles K; Marvanykovi F; Racz J
Neuropsychopharmacol Hung; 2012 Mar; 14(1):7-17. PubMed ID: 22427466
[TBL] [Abstract][Full Text] [Related]
17. Assessment of differential doses of buprenorphine for long term pharmacotherapy among opiate dependent subjects.
De S; Jain R; Ray R; Dhawan A; Varghese ST
Indian J Physiol Pharmacol; 2008; 52(1):53-63. PubMed ID: 18831352
[TBL] [Abstract][Full Text] [Related]
18. Diffusion and diversion of suboxone: an exploration of illicit street opioid selling.
Furst RT
J Addict Dis; 2014; 33(3):177-86. PubMed ID: 25115236
[TBL] [Abstract][Full Text] [Related]
19. A pilot study of buprenorphine-naloxone combination tablet (Suboxone) in treatment of opioid dependence.
Bell J; Byron G; Gibson A; Morris A
Drug Alcohol Rev; 2004 Sep; 23(3):311-7. PubMed ID: 15370011
[TBL] [Abstract][Full Text] [Related]
20. Buprenorphine and naloxone co-administration in opiate-dependent patients stabilized on sublingual buprenorphine.
Harris DS; Jones RT; Welm S; Upton RA; Lin E; Mendelson J
Drug Alcohol Depend; 2000 Dec; 61(1):85-94. PubMed ID: 11064186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
